These findings suggest that if TIL can be provided with 4-1BB expression, then 4-1BB agonism may be utilized as an adjunct to PD-1 blockade, even in those tumor types or patients whose TIL may lack native 4-1BB expression. Here, TNFRSF9 is linked to neoplasm.